Donor mobilized peripheral blood T cells (MPB T cells)

Donor mobilized peripheral blood T cells are T lymphocytes harvested from a healthy donor's peripheral blood following the administration of mobilizing agents such as Granulocyte Colony-Stimulating Factor (G-CSF) or Plerixafor [1]. These agents induce the egress of hematopoietic stem cells and various immune effector cells from the bone marrow into the peripheral circulation, allowing for efficient collection via apheresis [2]. In the context of allogeneic hematopoietic stem cell transplantation (HSCT), these cells are critical for establishing immune reconstitution in the recipient and mediating the graft-versus-leukemia (GVL) effect, which helps eliminate residual malignant cells [3]. However, the infusion of these T cells also carries a significant risk of graft-versus-host disease (GVHD), where the donor cells recognize and attack the recipient's healthy tissues [4]. Beyond direct transplantation, these cells serve as the primary substrate for the production of advanced cellular therapies, including allogeneic chimeric antigen receptor (CAR) T cells [5]. Managing the balance between GVL and GVHD remains a central challenge in the clinical use of these cells.

Other names

Mobilized peripheral blood mononuclear cellsG-CSF mobilized T cellsAllogeneic T cellsDonor lymphocyte infusion cellsD-MPB T cells

Mobilization of immune cells from bone marrow to peripheral blood via G-CSF signaling or CXCR4 inhibition; therapeutic action via T-cell receptor (TCR) mediated recognition of alloantigens or tumor-associated antigens.